Active	Status	Sponsor type	Region	Phase	Filter
3 Active 11 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dore, Greg
STRIVE-4, NCT03855917: Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir	Recruiting	4	30	RoW	Sofosbuvir 400mg [Sovaldi], Sovaldi, Glecaprevir/pibrentasvir (300mg/120mg), Maviret	Kirby Institute	Hepatitis C	02/26	02/26
CEASE, NCT02102451: Control and Elimination Within Australia of Hepatitis C From People Living With HIV	Active, not recruiting	N/A	492	RoW		Kirby Institute	Hepatitis C, HIV, HIV-HCV Coinfection	12/22	12/22
Dore, Gregory
REACH-B, NCT04914611: Real World Assessment of People Living With Chronic Hepatitis B in Australia	Recruiting	N/A	10000	RoW	No intervention	Kirby Institute	Hepatitis B	07/26	07/27